Table 1 Univariate analysis of overall survival
Overall survival at 1 year (%) | p-value | |
|---|---|---|
Age | ||
≤71 years (n = 61) | 74 | |
≥72 years (n = 55) | 64 | 0.069 |
Interval myeloma diagnosis to radiotherapy | ||
≤15 months (n = 66) | 76 | |
>15 months (n = 50) | 59 | 0.15 |
Other osseous myeloma lesions | ||
No (n = 46) | 75 | |
Yes (n = 70) | 65 | 0.15 |
Myeloma type | ||
IgG (n = 72) | 80 | |
Others (n = 44) | 52 | <0.001 |
Gender | ||
Female (n = 48) | 62 | |
Male (n = 68) | 75 | 0.15 |
Time developing motor deficits | ||
≤14 days (n = 50) | 55 | |
>14 days (n = 66) | 79 | 0.09 |
Number of vertebrae affected by SCC | ||
1–2 (n = 55) | 69 | |
≥3 (n = 61) | 69 | 0.54 |
ECOG-PS | ||
1–2 (n = 74) | 85 | |
3–4 (n = 42) | 36 | <0.001 |
Ambulatory status prior to radiotherapy | ||
Ambulatory without aid (n = 37) | 82 | |
Ambulatory with aid (n = 52) | 77 | |
Not ambulatory (n = 27) | 32 | <0.001 |
Fractionation regimen | ||
Short-course radiotherapy (n = 39) | 68 | |
Longer-course radiotherapy (n = 77) | 69 | 0.88 |